Abstract
Optimizing the Natalizumab Dose Interval to Reduce PML Risk- Lessons from the Pharmacokinetics of Therapy Discontinuation (P4.032)
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have